Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults.
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2015
At a glance
- Drugs Meningococcal vaccine group B OMV (Primary)
- Indications Meningococcal group B infections
- Focus Pharmacodynamics
- 27 Mar 2012 Actual end date (Jan 2005) added as reported by ClinicalTrials.gov.
- 27 Mar 2012 Actual initiation date (Jan 2005) added as reported by ClinicalTrials.gov.
- 22 Jan 2011 New trial record